• Je něco špatně v tomto záznamu ?

RNA methylation sequencing shows different gene expression signatures for response to azacytidine therapy in high-grade myelodysplastic syndromes

D. Gulei, V. Moisoiu, D. Kegyes, R. Drula, S. Iluta, AB. Tigu, M. Nistor, C. Jitaru, A. Bancos, P. Rotariu, C. Popovici, D. Dima, R. Tomai, I. Rus, C. Constantinescu, R. Munteanu, D. Cenariu, U. Sezerman, M. Zdrenghea, J. Cermak, H. Einsele, G....

. 2024 ; 28 (18) : e70078. [pub] -

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019020

Myelodysplastic syndromes (MDS) are myeloid malignancies with heterogeneous genotypes and phenotypes, characterized by ineffective haematopoiesis and a high risk of progression towards acute myeloid leukaemia (AML). Prognosis for patients treated with hypomethylating agents (HMAs), as is azacytidine, the main drug used as frontline therapy for MDS is mostly based on cytogenetics and next generation sequencing (NGS) of the initial myeloid clone. Although the critical influence of the epigenetic landscape upon cancer cells survival and development as well on tumour environment establishment is currently recognized and approached within current clinical practice in MDS, the heterogenous response of the patients to epigenetic therapy is suggesting a more complex mechanism of action, as is the case of RNA methylation. In this sense, the newly emerging field of epitranscriptomics could provide a more comprehensive perspective upon the modulation of gene expression in malignancies, as is the proof-of-concept of MDS. We initially did RNA methylation sequencing on MDS patients (n = 6) treated with azacytidine and compared responders with non-responders. Afterwards, the genes identified were assessed in vitro and afterwards validated on a larger cohort of MDS patients treated with azacytidine (n = 58). Our data show that a more accurate prognosis could be based on analysing the methylome and thus we used methylation sequencing to differentially split high-grade MDS patients with identical demographical and cytogenetic features, between azacytidine responders and non-responders.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019020
003      
CZ-PrNML
005      
20241024111132.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jcmm.70078 $2 doi
035    __
$a (PubMed)39334509
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gulei, Diana $u Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
245    10
$a RNA methylation sequencing shows different gene expression signatures for response to azacytidine therapy in high-grade myelodysplastic syndromes / $c D. Gulei, V. Moisoiu, D. Kegyes, R. Drula, S. Iluta, AB. Tigu, M. Nistor, C. Jitaru, A. Bancos, P. Rotariu, C. Popovici, D. Dima, R. Tomai, I. Rus, C. Constantinescu, R. Munteanu, D. Cenariu, U. Sezerman, M. Zdrenghea, J. Cermak, H. Einsele, G. Ghiaur, C. Tomuleasa
520    9_
$a Myelodysplastic syndromes (MDS) are myeloid malignancies with heterogeneous genotypes and phenotypes, characterized by ineffective haematopoiesis and a high risk of progression towards acute myeloid leukaemia (AML). Prognosis for patients treated with hypomethylating agents (HMAs), as is azacytidine, the main drug used as frontline therapy for MDS is mostly based on cytogenetics and next generation sequencing (NGS) of the initial myeloid clone. Although the critical influence of the epigenetic landscape upon cancer cells survival and development as well on tumour environment establishment is currently recognized and approached within current clinical practice in MDS, the heterogenous response of the patients to epigenetic therapy is suggesting a more complex mechanism of action, as is the case of RNA methylation. In this sense, the newly emerging field of epitranscriptomics could provide a more comprehensive perspective upon the modulation of gene expression in malignancies, as is the proof-of-concept of MDS. We initially did RNA methylation sequencing on MDS patients (n = 6) treated with azacytidine and compared responders with non-responders. Afterwards, the genes identified were assessed in vitro and afterwards validated on a larger cohort of MDS patients treated with azacytidine (n = 58). Our data show that a more accurate prognosis could be based on analysing the methylome and thus we used methylation sequencing to differentially split high-grade MDS patients with identical demographical and cytogenetic features, between azacytidine responders and non-responders.
650    _2
$a lidé $7 D006801
650    12
$a myelodysplastické syndromy $x genetika $x farmakoterapie $x patologie $7 D009190
650    12
$a azacytidin $x farmakologie $x terapeutické užití $7 D001374
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    _2
$a mužské pohlaví $7 D008297
650    12
$a metylace DNA $x účinky léků $7 D019175
650    _2
$a lidé středního věku $7 D008875
650    _2
$a transkriptom $x genetika $x účinky léků $7 D059467
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a epigeneze genetická $x účinky léků $7 D044127
650    _2
$a sekvenční analýza RNA $7 D017423
650    _2
$a protinádorové antimetabolity $x terapeutické užití $x farmakologie $7 D000964
650    _2
$a prognóza $7 D011379
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a methylace RNA $7 D000097906
655    _2
$a časopisecké články $7 D016428
700    1_
$a Moisoiu, Vlad $u University Hospital and University of Zurich, Zurich, Switzerland
700    1_
$a Kegyes, David $u Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania $u Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania $u Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania
700    1_
$a Drula, Rares $u Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
700    1_
$a Iluta, Sabina $u Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania $u Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania $u Department of Oncology, Bistrita Emergency Hospital, Bistrita, Romania
700    1_
$a Tigu, Adrian Bogdan $u Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
700    1_
$a Nistor, Madalina $u Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
700    1_
$a Jitaru, Ciprian $u Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania $u Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania $u Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania
700    1_
$a Bancos, Anamaria $u Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania $u Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania $u Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania
700    1_
$a Rotariu, Petra $u Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania
700    1_
$a Popovici, Corina $u Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania
700    1_
$a Dima, Delia $u Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania
700    1_
$a Tomai, Radu $u Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania
700    1_
$a Rus, Ioana $u Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania
700    1_
$a Constantinescu, Catalin $u Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania $u Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
700    1_
$a Munteanu, Raluca $u Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
700    1_
$a Cenariu, Diana $u Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
700    1_
$a Sezerman, Ugur $u Department of Biostatistics and Medical Informatics, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
700    1_
$a Zdrenghea, Mihnea $u University Hospital and University of Zurich, Zurich, Switzerland $u Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania
700    1_
$a Cermak, Jaroslav $u Laboratory of Anemias, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Einsele, Hermann $u Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania $u Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania $u Department of Internal Medicine II, Hematology, University Hospital Würzburg, Würzburg, Germany
700    1_
$a Ghiaur, Gabriel $u Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania $u Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania $u Department of Leukemia, Sidney Kimmel Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA $1 https://orcid.org/0000000239557944
700    1_
$a Tomuleasa, Ciprian $u Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania $u Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania $u Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania $1 https://orcid.org/0000000155001519
773    0_
$w MED00006785 $t Journal of cellular and molecular medicine $x 1582-4934 $g Roč. 28, č. 18 (2024), s. e70078
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39334509 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111126 $b ABA008
999    __
$a ok $b bmc $g 2201694 $s 1230993
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 28 $c 18 $d e70078 $e - $i 1582-4934 $m Journal of cellular and molecular medicine $n J Cell Mol Med $x MED00006785
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace